Molecular biomarkers in urothelial carcinoma of the bladder: Are we there yet?

George J. Netto

Research output: Contribution to journalReview articlepeer-review

98 Scopus citations


The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.

Original languageEnglish (US)
Pages (from-to)41-51
Number of pages11
JournalNature Reviews Urology
Issue number1
StatePublished - Jan 2012

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Molecular biomarkers in urothelial carcinoma of the bladder: Are we there yet?'. Together they form a unique fingerprint.

Cite this